Increased risks of all-cause mortality, fatal overdose, nonfatal overdose with PIP of opioids
MONDAY, Sept. 17, 2018 (HealthDay News) — Potentially inappropriate prescribing (PIP) of opioids is associated with increased risk of all-cause mortality and fatal and nonfatal overdose, according to a study published in the September issue of the Journal of General Internal Medicine.
Adam J. Rose, M.D., from RAND Corp. in Boston, and colleagues examined the correlation between PIP and adverse events in a cohort of 3,078,034 individuals aged ≥18 years without disseminated cancer who received prescription opioids between 2011 and 2015.
The researchers found that all six types of PIP were correlated with increased risk for all-cause mortality, while four and five of six were correlated with nonfatal overdose and fatal overdose, respectively. There were correlations for lacking a documented pain diagnosis and for high-dose opioids with nonfatal overdose (adjusted hazard ratios, 2.21 and 1.68, respectively). There was a correlation for co-prescription of benzodiazepines with fatal overdose (adjusted hazard ratio, 4.23). Correlations were seen for high-dose opioids and lacking a documented pain diagnosis with all-cause mortality (adjusted hazard ratios, 2.18 and 2.05, respectively). The hazard ratios for fatal opioid overdose were 4.24, 7.05, 10.28, and 12.99, respectively, with one, two, three, and ≥four subtypes of PIP compared to those who received opioids without PIP.
“Our study implies the possibility of creating a risk score incorporating multiple PIP subtypes, which could be displayed to prescribers in real time,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Withdrawal From Medetomidine Increasingly Seen in ICUs
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria